Bulletin of Experimental Biology and Medicine

, Volume 160, Issue 3, pp 336–339 | Cite as

Antiepileptic Activity of a New Derivative of Benzimidazole RU-1205

  • A. A. Spasov
  • K. Yu. KalitinEmail author
  • O. Yu. Grechko
  • V. A. Anisimova

Antiepileptic activity of a new derivative of benzimidazole RU-1205 was studied on the model of pentylenetetrazole-induced generalized seizures in mice. Sodium valproate was used as the reference substance. RU-1205 was superior to sodium valproate by anticonvulsant activity (by 12 times) and therapeutic index (by 8.5 times). In contrast to sodium valproate, RU-1205 exhibited significant anticonvulsant activity on the model of pentylenetetrazole-induced kindling without tendency to resistance development.

Key Words

kindling pentylenetetrazole antiepileptic activity anticonvulsant effect epilepsy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    T. A. Voronina, and L. N. Nerobkova, Methodical Guidelines for Investigation of Anticonvulsant Activity of Pharmacological Substances. Manual for Preclinical Studies of Drugs [in Russian], Moscow (2012), Pt 1, pp. 235-251.Google Scholar
  2. 2.
    O. Yu. Grechko, A. A. Spasov, D. M. Shtareva, and A. I. Rshchenko, Vestn. Volgogr. Gos. Med. Univer., No. 1, 61-63 (2014).Google Scholar
  3. 3.
    A. A. Spasov, O. Yu. Grechko, D. M. Shtareva, et al., Vestn. Volgogr. Gos. Med. Univer., No. 2, 120-122 (2014).Google Scholar
  4. 4.
    T. Y. Chen, H. T. Liu, C. L. Lee, et al., Tzu Chi Med. J., 20, No. 4, 280-285 (2008).CrossRefGoogle Scholar
  5. 5.
    A. Dhir, Curr. Protoc. Neurosci., Ch. 9, Unit 9.37 (2012).Google Scholar
  6. 6.
    R. M. Kaminski, J. M.Witkin, and T. S. Shippenberg, Neuropharmacology, 52, No. 3, 895-903 (2007).PubMedCrossRefGoogle Scholar
  7. 7.
    J. Kloke and J. Hardin, Curr. Protoc. Essential Lab. Techniques, doi:  10.1002/9780470089941.eta04as00 (2008).Google Scholar
  8. 8.
    S. Loacker, M. Sayyah, W. Wittmann, et al., Brain, 130, Pt 4, 1017-1028 (2007).PubMedGoogle Scholar
  9. 9.
    W. Löscher, Jasper’s Basic Mechanisms of the Epilepsies, 4th ed., Eds. J. L. Noebels, M. Avoli, M. Rogawski, et al., Bethesda (2012).Google Scholar
  10. 10.
    A. Manocha, P. K. Mediratta, and K. K. Sharma, Pharmacol. Biochem.Behav., 76, No. 1, 111-117 (2003).PubMedCrossRefGoogle Scholar
  11. 11.
    N. N. Nalivaeva, N. D. Belyaev, and A. J. Turner, Trends Pharmacol. Sci., 30, No. 10, 509-514 (2009).PubMedCrossRefGoogle Scholar
  12. 12.
    Y. Ohno, S. Ishihara, R. Terada, et al., Epilepsy Res., 89, Nos. 2-3, 360-364 (2010).Google Scholar
  13. 13.
    C. Schwarzer, Pharmacol. Ther., 123, No. 3, 353-370(2009).PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    A. A. Spasov, I. N. Yozrhitsa, L. I. Bugaeva, and V. A. Anisimova, Pharm. Chem. J., 33, No. 5, 232-243 (1999).CrossRefGoogle Scholar
  15. 15.
    The Opiate Receptors, Ed. G. W. Pasternak, New York (2011).Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • A. A. Spasov
    • 1
  • K. Yu. Kalitin
    • 1
    Email author
  • O. Yu. Grechko
    • 1
  • V. A. Anisimova
    • 1
  1. 1.Volgograd State Medical UniversityVolgogradRussia

Personalised recommendations